Alpha Tau treats first patient in European ACAPELLA pancreatic cancer trial

• Alpha Tau Medical reported first European pancreatic cancer patient treated with its Alpha DaRT device in ACAPELLA, a multicenter trial for inoperable locally advanced pancreatic cancer.
• ACAPELLA is testing Alpha DaRT combined with capecitabine as a potential post-chemotherapy option for patients who completed first-line mFOLFIRINOX, a setting with no standard consolidation therapy.
• Initial clinical updates from Alpha Tau’s pancreatic cancer program will be highlighted at Digestive Disease Week in Chicago on May 2-5, 2026.
• Alpha Tau positioned ACAPELLA as a key part of its European expansion strategy alongside its ongoing IMPACT pancreatic cancer trial in the US.
• Management framed the European start as an effort to build evidence for intrapancreatic alpha-emitter radiotherapeutics, targeting a high-need population with poor prognosis.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alpha Tau Medical Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604230901PRIMZONEFULLFEED9695737) on April 23, 2026, and is solely responsible for the information contained therein.